Questions Answered in the Video…
6. How rare/common are incidents like the one that occurred in New Mexico?
7. Why did it occur?
Important Notice from the Cellular Medicine Association–the recent incident in New Mexico took place at a center illegally using our name (Vampire Facial®). Qualified medical professionals handle blood all day long without serious problems and this procedure is even safer since it’s done with the patient’s own blood. But done improperly–people can be killed by cross-contamination. The providers in this article were imposters.
This is the official website to find those who have been certified to do the procedure by the Cellular Medicine Association and where you can read the research–click to see our directory<– Providers found there agreed to use devices approved by the FDA to both prepare the blood and to do the micro-needling. Anyone advertising the Vampire Facial® who is not listed there is stealing intellectual property and cannot be trusted. See PubMed & our website for more research
The Vampire Facial® name is owned by Charles Runels (see the website for the US Patent & Trademark office), although the name is currently under attack by those who would want free use of the name to sell devices and procedures without regard for our standards.
Someone using the name —as described in this article (click)—to trick people is exactly like someone making a fake Tylenol bottle and putting poison in it. Please—buyer beware! Only providers listed on our official website should be trusted to do the procedure.
We do our best to shut down the imposters. We list those we have found to be imposters/infringers at the website for the Cellular Medicine Association. But, the legal wheels turn slowly and expensively so people still use our good reputation to trick people.
Woman dies in the office of a massage therapist advertising the Vampire Facelift® (if you read the article, you’ll see the person actually died from a buttocks injection of something other than blood (probably something from the hardware store–NOT from a Vampire Facelift®). This woman would have never been accepted into our provider group and was using our name illegally.
Woman possibly contracts infectious disease from someone illegally using the Vampire Facial® name (again someone who never was part of our group, could never have been part of our group, and who was using our name-“Vampire Facial®” illegally).
Where to see infringers under notice or under litigation by the Cellular Medicine Association–those people who are using our names illegally or who have used our names illegally (these are those who are not to be trusted because are NOT certified to use our names but have been identified as illegally advertising)<–
This nih-Harvard-Berkeley researcher tells all…
Charles Runels: So, we’re honored tonight to be here with Kryz Bojanowski, Dr. Kryz Bojanowski, PhD. — who was the inventor of the patented ingredient that makes Altar™ cream what it is, that makes it not like anything else on the planet. So, thank you for talking with us Dr. Bojanowski. We’re here in southern California, and it was quite a journey. Two and a half hours for Dr. Bojanowski traveling to be here to talk with us about this cream.
Now, this cream came out of, not a frivolous project. I know that there was some study about how to treat some of the complications of diabetes. Will you just talk with us some about, what was the idea that prompted the development of the main ingredient in Altar cream?
Kryz Bojanowski: Yes, so, we started of by studying the diabetic skin as a model for accelerated aging. In the human body, the people with diabetes have an accelerated senescence of their skin, and it’s the perfect model to study the wound healing, because those people get wounds much more easy and it’s more difficult to heal them. So, me coming from a perspective, from a background of studying wound healing and skin vascularization, I was compelled to develop a product which would help skin of diabetic people, which will translate into an anti-aging product in general.
Charles Runels: Talk to us more about your background. How were you educated and how did you come to be studying this process in the beginning? What’s your story?
Kryz Bojanowski: Well, it started once upon a time, I was studying molecular cancer from oncology and my PhD is in molecular and cellular oncology of cancer. I spent 6 years in the University of Paris, studying the processes which are related to development of cancer, to regenesis, and how to control those processes. This brought me for postdoctoral training to Harvard Medical School, where I continued this cancer research. I specialized most in skin cancer treatment, and finding new treatments for skin cancer.
From there, when I moved to California, I worked at Lawrence Berkeley National Lab for some time, studying genes especially, and cancer cells, normal cells, skin cells, and from there it was only one small step to really getting involved in the wound healing, in the skin regeneration processes, which basically implore the same mechanisms than cancer, actually, except that it’s for a good purpose as compared with cancer which are suppressed, and out of control.
In the wound healing, in the skin regeneration processes, those are controlled processes that the body controls better if you can put it on the right direction. So, I was fascinated by this apparent parallel between wound healing and cancer. I wanted to understand what are the differences which make them, so similar yet so different, and different outcomes. We found out that there’s a big need for compounds which will accelerate wound healing, and which will accelerate the skin regeneration, either with, or even without wounds. In diabetic patients, people have wounds, but even without wounds, their skin is deteriorating much faster than in normal people.
Charles Runels: It’s easy to tear?
Kryz Bojanowski: It’s easy to tear, it’s easy to get some micro crack, which will develop in the hard to heal process. We were looking for a compound which can, first of all, prevent this from happening, because, you know, prevention is very important. It’s much easier to prevent than to treat what’s happened. Yet, when the things really happen, how can we can stop the degeneration process? How we can stimulate the wound closure and healing?
We found out that there is a process called angiogenesis, which is growth of blood vessels, which is very important for the proper healing of the wounds. Diabetic people have a very poor continuous circulation, very often. This is a factor which place in the difficulty of their wounds to heal.
So, we looked for compounds which can support the growth of blood vessels, which can support the stability of the blood vessels, because blood vessels may be leaking, can be not strong enough, can break, can have hemorrhages. This is what basically happens in cancer, the blood vessels are very leaky, and this is one of the factors that I worked on, how to make the blood vessels more, in French you say, [French phrase], less prone to leaking.
Charles Runels: Okay.
Kryz Bojanowski: We realized that this can have a very important implication for healing of wounds, and for the skin regeneration in general.
Charles Runels: Right.
Kryz Bojanowski: When the density of blood vessels decreases in the human skin, and with this decrease you also get a decrease of oxygen being transported to the skin. You cannot evacuate the metabolic waste, the cells become senescent, and all those are factors which play a big roll in skin aging and in the ability of healing of wounds in diabetic skin, and not only diabetic skin.
So, we developed this product. You know, we screened a lot of natural compounds, because it was important for us that it was a natural compound. We had a kind of, what is called HTP platform [inaudible 00:07:29] screening platform, which allowed us to zero in, isolate a couple of [inaudible 00:07:38] candidates, which we then tested on several different animal models, enzymatic models. We grafted human skin on mice and we wounded the skin, and we looked how the skin heals the wound in the presence of our compounds.
Charles Runels: So, is that the platform you’ve referring to?
Kryz Bojanowski: Yes, actually, the platform is multi-level. First you have the screening platform, which is in vitro platform in the kind of 96, in 96 well agar plates.
Charles Runels: Okay.
Kryz Bojanowski: Then you select couple of compounds which are the best being the most hoped-
Charles Runels: So you have tissue growing on a plate? You have cells growing-
Kryz Bojanowski: We have cells growing on the plate, yes.
Charles Runels: Okay, beautiful. So they’re? Okay.
Kryz Bojanowski: Then you look at the processes which happen in those cells. You can measure those processes by measuring the expression of genes. There’s the technique of PCR, polymerase chain reaction, which was used for that. You can use enzymatic analysis, you can use immunoflorescence, you can use lot of techniques to zero on the compounds which are the most promising ones.
Charles Runels: Okay.
Kryz Bojanowski: So, from there you go to the next level, which is animal study. We use either genetically diabetic mice, which are genetically prone to diabetes, they develop diabetes after a certain time, or you can use immunodeficient mice, which don’t have their own immune system, so you can graft the human explants from the surgery waste material, on them, and then you can work on those human skin splat supported by the animal.
At the end you have the patients to whom we give this compound, and they put it on their skin. We formulate it, and they put it around their wounds, and that was the ultimate level of validation.
Okay, so after validating the most promising compounds in the cellular model, we transitioned to the animal model, and for that we needed grafts from National Institutes of Health. This is a very expensive study, it’s a series of studies. It requires sophisticated angle of strengths, which are genetically diabetic, or which are immunodeficient.
So, after validating the most promising compounds in those animal studies, we formulated this molecule, and we applied it to volunteers under the supervision of pediatric doctors or family doctors, or doctors who are responsible for patients with diabetes, ‘diabetologists.’ They gave this product to the patients to apply on their skin, and around their wounds. We did several types of measurements. We measured the skin oxygenation, because this was the most important thing that we were looking for; whether or not this cream allows a better oxygenation, better vascularization of the patient’s skin. We measured the transepidermal water loss to see if the barrier function of the skin is improved with this product. We measured skin elasticity, and what else? The skin thickness. All those parameters turned out to be increased by the application of the product after 15 to 30 days.
So, the skin was more elastic, the skin was more oxygenated. We used a very sophisticated partial oxygen pressure meter to measure the oxygenation of the skin. The transepidermal water loss was decreased. So, we got all the parameters improved that we were looking for. Then, and only then we decided, okay, this cream, maybe now, put forward to see the world and to be commercialized.
Charles Runels: Beautiful. So, that whole process took how much time? From the time that you started testing on the plates, is that where you would mark the beginning? Or before that? Before that you had to think about what to put on the individual plates.
Kryz Bojanowski: Yes.
Charles Runels: How did you come up with the list of the things you tested?
Kryz Bojanowski: Well, we looked mostly for compounds which make up some merit, or make up some hope to improve the circulation. This was not a very kind of straight forward thinking, because when you look for skin products and skin additives, you don’t really think about the circulatory system more about your epidermis, dermis, keratinocytes, fibroblasts, skin cells. But here we actually took a more kind of holistic, more wholesome approach and we looked for compounds which may be beneficial for the blood circulation in general.
Charles Runels: Mm-hmm (affirmative)
Kryz Bojanowski: And so we looked for medicinal plants which have some track record of benefit for heart, for blood vessels, for bleeding, things like that. So one of those compounds turned out to be isolated from a Chinese medicinal plant called Angelica sinensis, which is considered in Asia to be like an equivalent of ginseng usable for the female part of the population.
Charles Runels: Mm-hmm (affirmative)
Kryz Bojanowski: And I learned that actually this compound and the plant where this compound is prevalent is taken by one who have a prolonged menstruation which cannot be easily naturally stopped, they continue bleeding and so we rationalized that this bleeding may be due to the fact that the blood vessels cannot be sealed, cannot be healed. And that’s why the bleeding continues.
So we were looking for a compound which is going to make those blood vessels stronger. So I immediately thought this may be a good candidate for our search. And indeed, we did our first studies on the micro-circulation in vitro. You can make a kind of three-dimensional network of blood vessels, using capillary blood vessels which you can make. But after a couple of days, those networks, they are outside of the body, they will fall apart.
And so we use this experimental system to study those different compounds to find out which compounds can support this network, to extend the life of this network, make it more kind of robust. So this is how we isolated our most promising lead candidate. And from there we did these annual studies and then we get to formulate this compound.
Because especially for the skin care, the compound itself can be very good but if it does not penetrate inside the skin, it’s useless. So it also has to be not irritating because the kind of very nice compounds which work very very well in vitro, and in vivo when in animal models, but when the patient puts it on the skin says, “Ooh, it stings,” and it is not comfortable. And so it’s not going to use it even if it’s going to provide the patient with a benefit.
So we formulated this compound, encapsulate it in a way that it’s not going to make the skin irritant and it’s not going to make the compound irritant, it’s going to provide penetration into the skin. So these were all those factors which we had to take in consideration beyond the active molecule that we developed.
Charles Runels: So I think you just partially answered this question, but for example, you can have a foxglove that becomes digitalis [when you isolate individual compounds and concentrate them from the foxglove plant], or you can have [the leaves of the willow tree that become] aspirin. You can have natural products or you can have the distillate … what’s the chemical that becomes … yohimbine [becomes Yocon]. But then if you get a very discrete, if you get a very nice isolate of it, it becomes a prescription drug, it becomes Yocon, which they took off the market when Viagra was approved.
It was actually a very good drug because it was a very concentrated isolate of yohimbine. So back to this product, what is it exactly that you did that made that natural product become more medicinal, more concentrated, less irritating? Did you change it biochemically, did you capsulate it somehow? What did you do to it to make it more medicinal and less like the natural root?
Kryz Bojanowski: Right, yes, that’s a very good question actually, because the answer is, we did both.
Charles Runels: OK.
Kryz Bojanowski: So first we isolated some fraction of this plant, of this root. And we refined it to the point that there were only very few molecules and only the molecules that you want there.
Charles Runels: OK. By a distillated process, or how did you isolate it?
Kryz Bojanowski: It’s a multi-step process, mostly by chromatography,
Charles Runels: OK.
Kryz Bojanowski: By filtration,
Charles Runels: OK.
Kryz Bojanowski: By affinity chromatography,
Charles Runels: Yeah.
Kryz Bojanowski: So …
Charles Runels: ‘Cause this detail, sort of science, is the kind of step that you might … this is what you do in a day. But when people look at this product they might not have any idea what you did that took this natural root and turned it from foxglove into digitalis but so to speak metaphorically, you took a natural product and you turned into something much more usable and more effective.
So what you’re saying is by some multi-step, sort of through pass chromatography and some filtration systems, you took different chemicals that were in this natural root and you isolated a particular part of it that seemed to be doing most of the work, is that what you’re saying?
Kryz Bojanowski: Yes, yes. It was fractionation, which was based on biochemical properties of the different ingredients in the root…
Charles Runels: OK.
Kryz Bojanowski: And it’s called bioactivity-driven isolation.
Charles Runels: OK.
Kryz Bojanowski: So basically to start with, it’s kind of very difficult to isolate compounds from a botanical that you are sourced because it’s so full of molecules. Life is full of molecules. So we needed to design a method which would allow us to be guided by the bioactivity, to gradually isolate the less and less amount of the smaller and smaller fraction of those molecules from the root to the point that if you remove one it’s not going to work or it works less.
Charles Runels: Yes, so as simple as it needs to be with no more simple than that.
Kryz Bojanowski: Right, so it’s a kind of fine balance.
Charles Runels: Yes.
Kryz Bojanowski: So if it’s too much, you are going to tag along some compounds which may not be desirable.
Charles Runels: Yes.
Kryz Bojanowski: If you purify too much, you are going to lose activity. Because very often in life, things are happening well because of one molecule.
Charles Runels: Yes.
Kryz Bojanowski: Very often it is combined activity, synergistic activity of several compounds which basically make things happen. So our pharmacological approach to medicine is basically purify one molecule, make it as pure as possible, make it into a drug, which, intellectually speaking, no, scientifically speaking, is very accurate. But very often you pass, you miss some activities which could be much better if you could leave a couple of compounds together. It would be a not so much defined product but still very, very useful.
Charles Runels: OK.
Kryz Bojanowski: And so we decided not to go all the way to the pharmacological grade of our preparation, which would allow us to file NDA and get a prescription medication status because we would lose this, at least partially, this activity which is contained in a multi-component preparation. So we stopped at the kind of border between multi-component and pharmaceutical grade.
Charles Runels: So I’m taking it that you can test it both sides of that line to figure out where to stop, is that correct?
Kryz Bojanowski: Yes, yes. We of course did many isolation repeats. It was a kind of trial-and-error process and that’s why it took such a long time, six years, right.
Charles Runels: Yeah.
Kryz Bojanowski: So we finally ended up with this minimum necessary amount of compounds which are going to provide optimal activity for the blood vessel support and the skin regeneration.
Charles Runels: Six years.
Kryz Bojanowski: Six years.
Charles Runels: Yes.
Kryz Bojanowski: Yes. And it could have been much longer if we didn’t get the support from the government, from the NIH, so that was actually quite big support.
Charles Runels: Meaning that you had other people helping you with the study.
Kryz Bojanowski: Well, there was a funding from the National Institutes of Health because we also developed a wound dressing which is a companion to the skin care product. But also of course I wouldn’t be able to do it by myself, I mean, these scientists, they don’t work solo. They have teams. So I was fortunate enough to have a good team of colleagues and technicians who really put their energy and their heart into this project.
So once we had this multi-component botanical isolate, we needed to formulate it in a way that it’s not going to be irritant to the skin of the patients and which will allow the active materials to penetrate into the skin. And that was another challenge. It’s actually often underestimated how much effort has to go into formulation of those active materials for the skin.
So most of the skin care products, they are called oil-in-water emulsions. So basically you have the lipophilic compounds which are surrounded by the water like film. And we took an alternative approach. We actually got a water-in-oil formulation which is more difficult to make, which takes more effort and more research to standardize, but which allows you to have a kind of packaging which is friendly to the skin.
Because skin is mostly composed of layers, right? So you need a like packaging which is going to interact with the stratum cornea which is this upper layer of the skin, of the epidermis, to allow the compounds to be then kind of introduced into the lower layers of the epidermis and even to the dermis.
So this water-in-oil solution allowed first the oil to contact the skin and then kind of dissolve into the oil, lipidic membrane, and then allow to introduce the active compounds which are water soluable, inside a skin.
Charles Runels: So the oil acts as a carrier to allow the aqueous part to then penetrate behind it somehow, is that-
Kryz Bojanowski: Yes, yes, that’s correct.
Charles Runels: So what you’re describing now is the formula for what’s the other ingredients in the package, Altar™, is that correct? This formula for the water and oil is the thought process that went into the other ingredients.
Kryz Bojanowski: That’s right.
Charles Runels: Can you specifically tell me some of the things in the list that accomplish what you just talked about?
Kryz Bojanowski: Well, as you can see, there’s a lot of compounds.
Charles Runels: Yes.
Kryz Bojanowski: And there’s a story behind each of the compounds.
Charles Runels: Yeah.
Kryz Bojanowski: And so, for example, the Dimethicone is FDA approved skin soothing compound. There is a, how do I say… This is a very interesting compound between what we worked separately on and we found out that the hydrolyzed silk, basically it’s a protein. And this protein is very good at simulating collagen expression. Now we go back to the laboratory studies. One of the studies that we did is to assemble some of those components and put them on the skin and measure gene expression in the skin. Basically, by measuring the gene expression you have a genetic print out of the… You learn what is the genetic response of the skin to the formulation that you are planning. So this is also something that we did it, the time that we did it was very unusual to do, because you don’t look at 70,000 genes; that’s the amount of genes we have in our body; enough to formulate a skincare product, but we did just that.
We did what is DNA microarray study which allows to measure the expression of every single gene in the tissue. So in our case it was steep and we measured, we quantified the expression of those genes with or without our formulated product.
Charles Runels: With the hydrolyzed silk?
Kryz Bojanowski: With the hydrolyzed silk, yes. And we found out that hydrolyzed silk adds to the benefits of the angelica sinensis extract. So that’s what only some of those share but it’s a very good oil which provides an lipihilic kind of environment.
Charles Runels: So is that part of the care here you’re talking about?
Kryz Bojanowski: It’s a part of the care. It’s not just like two compounds that you would, it’s not like two level blocks that you put together. It’s more like a meshed entity. It’s a kind of integral structure which is formed between a few compounds which are towards the outside with the formula becoming hydrophilic when you get inside the formulation. The formulation you can think about, that’s about like liposomes or micelles and that’s like an ingredient of hydrophobicity from the outside to the inside. Different components occupy different layers in this grid.
Charles Runels: So I noticed when I use it, that it does have an exceptionally just smooth, pleasant feel to it. Is that what I’m feeling? That sort of lipolytic outer layer, the aqueous, what would you attribute to the fact that it just feels very soothing? Is that the whole recipe-
Kryz Bojanowski: Yeah, it’s like chef cooking a special dish!
Charles Runels: So how many years did you work on this recipe?
Kryz Bojanowski: Well 6 years of actual testing.
Charles Runels: Just on the one ingredient?
Kryz Bojanowski: On the one ingredient. Well we did it testing in parallel in several ingredients. So if you add all of the years of experience, of work on each of the components, it’s going to be probably close to maybe half a century.
Charles Runels: Are you half a century?
Kryz Bojanowski: Half a century?
Charles Runels: Are you a half a century old?
Kryz Bojanowski: Well that’s actually I am getting there.
Charles Runels: I think so to be plain that this is not a lotion that you cook up at the local dime store. This has a lot of thought that you’re allowing us to make it part of our procedure, because I think we have an amazing group of doctors working– we are now in over 50 countries and it’s about 2,000 of us–really brilliant physicians in multiple universities. And I’ve had a lot of people bring stuff to our group that I’ve said “no” to for 8 years. It went from nothing was good enough for us to now I’m actually honored that we’re able to offer this as part of our procedure, because I think it obviously it contains a big piece of the life of a brilliant man built into it. So I’m very grateful that-
Kryz Bojanowski: The honor is the product. I also feel that this product really fits perfectly into your strategy, because of it effect on the strength of the blood vessels; and also in the skin, the regenerative, the healing potential on the skin, which I think is going to be very well matched with your products. Which needs to be introduced by puncturing the skin gently and this product is going to allow those patches to go away in no time. I think it’s the perfect match.
Charles Runels: Yes! When we use PRP, we have biopsy studies that show the PRP causes neovascularization, fibroblast activity, and the idea that we now have a cream that does the same thing at the same time–it’s no wonder that we’re seeing really miraculous results. We have other procedures, other than facial procedures, that we’re doing. For example, we have a procedure where we use PRP therapy [Vampire Wing Lift™] to regenerate some of the appearance and the function of the labia and some of the sexual tissues. Anecdotally, some patients told me that even post waxing the labia using this has a calming effect and a healing effect. Waxing can be pretty brutal to the skin or just shaving. Post shaving the labia where the tissues are so fragile, using [Alter™] afterwards can have an amazing effect.
Just think about the drugs. You do thousands of test and millions of dollars; and you put it in the hands of the consumers, and they reflect back at you because there’s a sizable number of people using it, and then stuff you haven’t thought about starts to be known. It’s going to be fun over the next few years to see what happens when we put it in the hands of our providers and in the hands of thousands of patients.
Kryz Bojanowski: Yes, I feel like my baby grew up and left the house. I don’t have control of it. But it’s interesting what you said about the shaving; because it comes back to this idea of the female ginseng I think that in Asia, this plant is being used by the female population predominately. Maybe because there are some specific benefits to the gender.
Charles Runels: I need to be careful. I’ve been putting it on the scrotum and the penis. I just need to tell you right now. For me that’s important that that stays healthy too. If you’re gonna have fewer older cells, why not put it on your penis. So I’ve been putting it on my scrotum and my penis and I think its happier-
Kryz Bojanowski: Well it’s skin. You have skin, wherever you have skin.
Charles Runels: So this plant from which the isolate is made, are we going to run out of that? Where does it grow? I haven’t seen it growing… obviously it’s in China and it’s in other places. Are we going to say “oh this product is wonderful” then all of a sudden we can’t get the plant anymore.
Kryz Bojanowski: That’s a good question because I was referring to a female ginseng. It’s not like ginseng which you have to go to the mountains to hunt-
Charles Runels: Which I’ve done before. It’s very hard to find.
Kryz Bojanowski: So this one is actually cultivated. It can come from organic fields. So it can be certified organic. There’s a control over the supply. We don’t need to worry about that.
Charles Runels: Good. Glad to hear that. I’m really honored to talk to you. I think that’s all the questions I have for you. I’m going to invite our providers to write in and blog, and the people who use it, to let us know. Hopefully they’ll teach us more about your baby. What it could be used for. I do think it’s going to take a life of its own. I’m really grateful to you for thinking it up.
Kryz Bojanowski: So, I give it to you now.
Transcript of the Video Can be Found Below…
The normal time for physicians to accept a new procedure is 20 years (10 to do the research and another 10 for physicians to routinely offer)…
Transcript of Above Video<–
Charles Runels: Hello, I’m Charles Runels, and I’ve recently been asked quite a few times, “Where did these ideas for the O-Shot and the Vampire Facelift,” I did design those procedures, “Where did they come from, and who are you?” I thought it might be helpful to know why initially I actually hid myself. I tried to stay secretive about where the idea originated, where they came from, and why I tried to stay hidden for at least two years.
A little bit about how I transitioned from being an internist slash emergency room doctor to becoming the guy who’s lecturing around the world about women’s sexuality. It wasn’t an intentional thing that I set out to do. What happened was, after 12 years in the emergency room I started taking care of women and doing hormone replacement before it was cool. 18 years ago in the year 2000 I was doing research with growth hormone, before Suzanne Somers wrote those books. Because of that, and because I was ahead of the curve somewhat as far as people knowing about these ideas about caring for women the way it’s commonly done now, back then the way to take care of a menopausal woman was to give her Premarin, and no one was really prescribing testosterone. If they did it was an old Premarin missed with testosterone. It was just a completely different level. Nobody was measuring hormone levels to speak of in normal post-menopausal women. It just wasn’t so good.
I became involved in the research out how to make that better, as an internist, but I had a background in research. I did three years as a chemist before I did medical school. But mostly I just had an intense desire to make women well. What broke my heart over and over and over again, with literally thousands of women, is they would come to my office and sob, and they would tell me, “I love my husband,” and I heard this story literally thousands of times. “I love my husband, so I don’t want to tell him that sex is not so good. Or that I don’t really desire him. And I don’t know why I don’t desire him, because I love him, and sex used to be wonderful, but I’m afraid I’ll hurt his feelings.” They’re sobbing, and they don’t know what to do.
Then I would do the things I knew what to do 18 years ago, doing these things with testosterone and thyroid, things that are commonly done now. Then often times the man would then not be able to keep up with the women, because her sexuality is better and her libido goes up, she loss weight, and she feels wonderful and sexy, and now her libido is outrunning his. So I started focusing on, how can I help this man catch up with the woman. 18 years ago, 2000, mostly it was just body builders that were using hormone replacement. You go back a little bit before that, we were still telling men that the most common reason for impotence was psychological. It’s hard to believe that, but in the 1980s when I was in medical school we thought, or it was taught, that 85% of men who had erectile dysfunction, it was psychological. That was actually taught to urologists, that they should become counselors. Then of course once we had all these medicines that help men, we knew it wasn’t al psychological. It’s the reverse, 85% of it was neurovascular.
I’m doing all this, and I’m taking care of women, and again, so how’d he go from there to coming up with a vagina injection, like the O-Shot? That’s the question people, “Who is this guy?” What happened was, in a lot of women, when they would try to lose weight, they would want to gain their weight back when they saw the fat go out of their cheeks, and when the adipocytes left and the wrinkles would appear, and they would feel older even though they were leaner. To counteract that I learned to do fillers, like Juvederm, in the face to bring their face back so they wanted to keep losing weight. I became, I think, good at it. I won’t say very good but some people say very good at it. I know this, I trained with the best in the world. So 10 years ago I started doing that.
Now I’m plugged into the aesthetic market, but I’m still doing it mostly to encourage people to lose weight, and then I discover how important it is to women, and how it’s changing their whole life when they feel better about their facial appearance. It makes them want to work harder on their health than their fitness. Now I’ve got these three little satellite things going on. I was a ex-research chemist who was interested in technology, helped design some things that are still used by our soldiers in defense work, and then I was involved with wound care, and healing and tissue growth, that’s part of the wound care in the hospital when I was a ER guy. Now I’m tuned into sexuality, not because I set out to do that, but because I was trying to take care of women who were just telling me what was wrong with them, and happened to be involved in some research about how to do that. So I’m taking care of the women’s sexuality with hormones, I understand wound care, and I’m doing cosmetic medicine.
Here’s what bothered me. This was to me, this still goes on and it really bothers me. What if, when you go down the street, all the signs for the restaurants just said “beef,” but you couldn’t tell if you were at a hamburger joint or a gourmet restaurant? Sometimes you might want one or the other, but at least you should know which one you’re getting when you walk through the door. Instead one says McDonald’s, I love McDonald’s, maybe I want McDonald’s one day but maybe I want a gourmet filet the next. That’s exactly what was going on with cosmetic medicine, and still goes on. Because you see not the procedure advertised, but the material. You see Juvederm advertised. Well Juvederm, you can take a syringe of Juvederm and make a woman look natural, and younger, and she can see her mother or her husband the next day, and they think, “Did you get some rest, you look great today,” and not even know something was done. Or you can take that same syringe of Juvederm and make her look like she’s got sausage for lips, or like she’s got Donald Duck for lips. If you see a doctor advertising Juvederm you don’t know which you’re going to get, because you’re just like seeing beef without knowing if you’re going to get a gourmet preparation or a fast-food hamburger.
I wanted to change that, but I didn’t really know how to change it, and I still don’t really know how to change it in the Juvederm world, but someone brought to me, and this is where the procedures happen, this is where all the starts collided. Back in 2010 someone brought to me a centrifuge that had been used by the orthopedic surgeons to prepare platelet-rich plasma for the knees, and by the dentists in wound healing. The person bringing the centrifuge says, “This has been FDA approved for preparing platelet rich plasma, and if you use it …” Of course it’s blood, the blood’s not FDA approved. The FDA doesn’t approve your hair, your urine, your saliva, or your blood, but they have to approve the device that makes the plasma to go back into your body. He says, “This has been FDA approved to prepare plasma to go back into the body, and it’s been shown to cause new tissue growth, new blood flow, new volume, and there’s never been a granuloma or a serious infection or a serious side effect from a platelet rich plasma. You should try it in the face.”
I thought, this is wonderful, because if this works in the face … Instantly, because I was tuned into the sexual problems, I thought if this works in the face and does all those things, then this should help the genitalia. Honestly initially I was thinking the male genitalia, but I was following the work that had been done by gynecologists when it comes to injecting around the urethra for sexual function and for urinary incontinence. So I’d been following that very carefully because I was involved with caring for women, but I thought, let me use it in the face first and see how it works, read the literature, learn how the thing works, and then I will use it in the genitalia. I started reading the literature, everything I could find about platelet-rich plasma. At that time there were 5,000 or so papers out, now there’s over 9,000 research papers, and I read thousands of them. I can’t tell you I read all of them, but I read a lot of them.
Then what I started seeing is, it really worked in the face, but I needed a name to call it, and I wanted it not to be a generic PRP, because I didn’t want to be advertising beef and you don’t know what you’re getting, or advertising Juvederm and you don’t know how it’s going to be used. I said let me give it a trial of having a name that means using this platelet rich plasma in a very expert way, and combining it with the Juvederm to create this gorgeous shape. If I can make that work in the aesthetic space, maybe I can make it work in the sexual medicine space and protect patients from having something done that would be, obviously metaphorically, the equivalent of a duck lip done in the genitalia. Could be devastating psychologically and physiologically, and I didn’t want stupid things being done to people’s genitalia, so I needed a way to protect it. You can’t protect the name platelet rich plasma, that’s the name of a body fluid, but I thought if I could organize a group of doctors around the procedure, then I could protect it if I owned the name of that procedure. Let me give it a try in the face first.
The press had used the word “vampire” already in association with PRP, but they were calling it vampire therapy, and I didn’t think … I particularly don’t want to have therapy, or they were calling it vampire filler, and I didn’t want to be filled up, but what I could see it was actually doing was causing a facelift. Lifting the tissue away from the skeleton, a way from the skull, and truly lifting it away back into a younger shape. That’s what I did with the material, and I said let’s call it the vampire facelift. I trademarked it, and I started recruiting physicians who would agree to follow the specific method that I developed, and to see if I could protect that method, and it just went crazy. It went berserk. The people loved the name, it was all over the press.
I spent the next two years … I tried to hide myself, because I didn’t want it to be about Charles, I wanted it to be like, who knows. You have to do research to figure out who owns McDonald’s, you just see the golden arches. I do not have a franchise, but the idea was, there’s a way that that is done, as in the way that hamburgers are made, and there’s a way to do this face, and I wanted only people who understood that way to be able to use my name. I didn’t want it to be about Charles, I wanted it to be about the patient and whoever was doing the thing.
To this day people get it confused. The New York Times interviewed me, and I love the New York Times, but they interviewed me and the reporter said, “Dr. Runels liked the name Vampire Facelift so much he trademarked it.” I did like it, because I thought of it, and when I Googled it in 2010 and first used it in early 2010 … Matter of fact, the first YouTube video I put out was on April 20, 2010, and when I put that out you could Google “Vampire Facelift” in quotation marks and you would get zero hits. I don’t know many things you can Google and nothing comes up, but that phrase, there was nobody else on the planet using it. I thought great, this is a name that I can circle around, and if we can stamp it out and protect it, this is what’s important to vaginas and penises, I said if I can stamp it out and protect the way this method is done, then I can make sure that nothing stupid gets done on a routine basis to women’s vaginas. I guess technically it is true that I liked it and so I used it, but I liked it because I thought of it.
As I worked with the faces, about four months into that I thought, let’s do this thing with penises, and then it evolved. Because basically a clitoris is embryologically like a small penis, so the first penis I injected was my own. At this point I’m still trying to hide the identity of me and promote the physicians that are agreeing to help me on this mission, the mission being, let’s do something about these women who are suffering. At that point we had not one drug approved for women. Not one FDA approved drug.
We have over 20 FDA approve drugs and devices for men, we have one FDA approved drug for women, and it’s a psych drug. I’m not saying it’s crap or that it should not be used, but I’m saying … That’s what we used to tell men, that it was all psychological, and the only drug we have now, it’s like saying we have one drug to help you and it’s a psych drug, so basically it’s all in your head. But if you can have problems with circulation in the penis, and a clitoris is like a tiny penis, it’s usually five inches long, you’re just seeing the tip of it when you look at it in the body, then you can have the same neurological, the same neurovascular problems, both nerves and blood flow, could go on with the clitoris. The same autoimmune process that causes lichen sclerosis of the foreskin of a man can cause it in a woman. Autoimmune processes are involved with Peyronie’s disease. All those things are analogous.
Anyway, back to the story, I started circling around and teaching and protecting the group for the face, and then forming the group for the penis, and then forming the group for women. When I started teaching people and they were saying, “Charles, this thing works,” I thought wow, it really does work, it’s not just me making this up. So we started doing research, and the research was positive. So far every study we’ve done, and we’re up to six studies, two in the works, every one of them has been positive, both with men with Peyronie’s disease, men with growth, rat studies showing new nerve growth when you inject the penis. Of course men don’t volunteer to have it chopped off, but if you inject the penis of a mouse and then you chop it off, the nerve grows back as it would if someone had prostate surgery and had nerve damage. We are seeing that happen.
Eventually though, this is what happened. Charles who was hiding eventually had to come out, because anything that’s valuable enough to get mentioned just last week in Allure magazine, Fox News, Cosmo, the Daily Sun, and the Daily Mail and the Sun, all of those in the past week, obviously that’s a lot of advertising, a lot of attention, and now some people want to pretend like they’re a part of our group when they’re not. Because of that, and only because of that, I’ve had to come out of the shadows and say, “Yeah, this is a thing, and don’t try to use it if you’re not part of our group, and if you do, this is the guy that’s going to have attorneys shut you down.”
Because I don’t like it when I have women, and this happens at least every other week, when I get an email from a woman who says, “I had this horrible procedure where it hurt like crazy and I bled and it didn’t do anything for me,” and I say, “Who did your procedure,” and they send me the name of someone who’s not in our group, doesn’t even know what they’re doing, never been trained by one of our teachers. We’ve got 50 or so teachers, a little more than 50 teachers, in 40-something countries and still growing, and so it’s still not about Charles. It’s about taking care of patients, it’s about doing the research, and we’ve spent hundreds of thousands of dollars on research, hundreds of thousands of dollars on attorneys taking up for people who had things done to them by people not in our group. We’ve spent hundreds on educational materials we give for free to our patients. We all do work for free for patients. Yeah, it’s not covered by insurance and some of them pay us money, but a lot of us do work for free as well.
The bottom line is, it’s still not about Charles, but Charles wanted to be a doctor when he was in the first grade. He wanted to do one little thing that might help medicine, and what’s happening is, Charles, through the doctors who have trusted this process, and the doctors who are also passionate about taking care of women and men … Because they know sex is not just about pleasure, it’s about putting relationships back together and keeping relationships together, when a family breaks there’s a ripple effect that causes anguish throughout the whole neighborhood. It’s not just the family, it’s the people at their work, at their church, at the school. The kids have to travel back and forth. There’s a social fiber that’s built around the family. Ray Bradbury said that the family, it’s the happiness machine. That’s what it is. Your family might be your dog, that’s wonderful. Your family might be your wife and your 10 kids. But whatever, your family is your happiness machine, and bad sex breaks that happiness machine down.
Here’s the thing. I’m a internist from Alabama. I’m not a plastic surgeon, gynecologist, urologist, I’m nothing fancy. But I think we have a mission that is world-changing, and I will be ferocious to anyone who tries to hurt that mission, and hurt anyone in our group, or hurt anybody who’s attracted to our providers because of our mission, and because of our message and our reputation and our research. If someone tries to be involved who isn’t legitimate, I will punish them as severely as I can no matter how much it costs. If someone wants to join our group, I will take our funds, and we spend hundreds of thousands of dollars every year, I will take our funds and I will help finance the research, I will have people be treated for free. Right now we have research going where people can be treated for free. I will protect, I will support, I will educate, I have literally flown around the world, I will do whatever it takes.
It really doesn’t need to be about Charles, but because people have asked, I’m telling you who I am, where I am. We have this great organization called the Cellular Medicine Association, and what really makes our mission work, which is change the fabric of the world by helping sexual health on a very basic cellular way. Then because of that sexual health the family’s made stronger. When we can do that, we have a reason for being here. We have a reason for using our brain. That’s what our doctors do, that’s what our researchers do, and that’s what I hope that you will help us do. I’m very grateful for your attention.
Cellular Medicine Association
Members of the Vampire Facelift® provider group, can login to the member’s site to see more specifics of how to use Vampire Amnion™ to rejuvenate the hands and face and to receive special pricing from the largest supplier of quality amnion in the U.S.
ONLY live birth amnion is used (no aborted fetal tissue).
Here’s the company that harvest the amnion for us (click)<–